94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Stroke
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1522598
This article is part of the Research TopicFrom bench to bedside: Inflammation in Neurovascular Disorders and StrokeView all 9 articles
The predictive value of stereotactic surgery guided by CTA angiographic point sign for secondary hematoma expansion following surgery in patients with moderate-volume basal ganglia hematoma
Provisionally accepted- 1Maoming People's Hospital, Maoming, China
- 2Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangx, China
- 3Baise City People's Hospital, Baise, China
- 4Youjiang Medical University for Nationalities, Baise, Guangx, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To examine the efficacy of the CTA angiographic point sign in forecasting secondary hematoma expansion following stereotactic surgery in patients with moderate-volume basilar ganglia hematoma and its potential to enhance postoperative outcomes. Methods: A retrospective analysis was conducted on the clinical data of 143 patients with moderate-volume basal ganglia hematoma (hematoma volume between 30 ml and 60 ml) admitted to the Department of Neurosurgery at Baise People's Hospital from January 2021 to December 2022. Stereotactic surgery guided by the CTA angiographic point sign was conducted in 79 patients (experimental group), while stereotactic surgery guided by the CT scan was performed in 64 patients (control group). The short-term clinical results (incidence of secondary hematoma expansion, GCS score within 30 days, death, surgical complications) and long-term clinical outcomes (MRS score after 6 months) were analysed by comparing the two groups. Results: No subsequent hematoma expansion occurrences transpired in the experimental group post-surgery, but 12 (18.75%) such events were observed in the control group following the procedure. The experimental group experienced 27 postoperative lung infections (34.18%), whereas the control group had 33 infections (51.56%). The average GCS score was (9.46±2.23) in the experimental group and (7.94±4.68) in the control group. The mortality rate was 2 (2.53%) in the experimental group and 8 (12.50%) in the control group. The treatment efficacy rate (MRS ) at 6 months was 59 cases (74.68%) in the experimental group and 35 cases (54.69%) in the control group. The disparity between the two groups was statistically significant (p<0.05). Conclusion: CTA angiographic point-guided stereotactic surgery can significantly diminish the incidence of subsequent hematoma expansion following the procedure, enhancing patient clinical outcomes and postoperative quality of life.
Keywords: point sign, moderate volume, Basal ganglia hematoma, stereotactic surgery, prognosis
Received: 04 Nov 2024; Accepted: 25 Mar 2025.
Copyright: © 2025 Peng, Zhen, Pin, cheng, Nong, Jing and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Liao Chang Pin, Baise City People's Hospital, Baise, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.